3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
3
Thoracic
1
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
105
Skin Neoplasms
17
Neoplasm Metastasis
15
Neoplasms
10
Uveal Melanoma
9
Carcinoma, Renal Cell
9
Carcinoma, Non-Small-Cell Lung
9
Kidney Neoplasms
6
Colorectal Neoplasms
6
Carcinoma, Merkel Cell
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Lung Neoplasms
3
Carcinoma, Transitional Cell
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Prostatic Neoplasms
2
Lymphoma
2
Eye Neoplasms
2
Carcinoma, Hepatocellular
2
Urogenital Neoplasms
1
Turcot syndrome
1
Sezary Syndrome
1
Sarcoma, Synovial
1
Interventions
pembrolizumab
4
Drug Therapy
3
Temozolomide
2
Radiation
2
Paclitaxel
2
Nivolumab
2
Cisplatin
2
Bevacizumab
2
vocimagene amiretrorepvec
1
ulixertinib
1
temsirolimus
1
selinexor
1
rovalpituzumab tesirine
1
regorafenib
1
pazopanib
1
niraparib
1
imetelstat
1
fludarabine
1
erythromycin propionate-N-acetylcysteinate
1
epacadostat
1
efineptakin alfa
1
durvalumab
1
dostarlimab
1
cobimetinib
1
cediranib
1
cc-486
1
carboxyamido-triazole
1
bemcentinib
1
aflibercept
1
WP1066
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
Interleukin-2
×
Dermatologic
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled